We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04750954
Title Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136 United States Details
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field